At Tonix, we are focused on identifying and developing candidates that have the promise to treat and prevent human disease and alleviate suffering. Through our own development, in-licensing, collaborations and acquisitions we are curating an innovative and effective portfolio that targets the relief of pain and attenuates infection. Currently, our pipeline is primarily comprised of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Our infectious disease portfolio includes a live virus vaccine platform, and a potential treatment for Long COVID. We are progressing small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions through our CNS portfolio.